PTGS2 and neoplasm: CA and GA showed the dose-dependent inhibition of COX-2 activity in ascites macrophages (CA by 70% or 100% and GA by 37.76% or 74.14%) and in tumor cells (CA by 39.76 or 63.22 and GA by 22.72 or 47.42).